» Articles » PMID: 35053224

Calcium Signaling Pathway Is Involved in the Shedding of ACE2 Catalytic Ectodomain: New Insights for Clinical and Therapeutic Applications of ACE2 for COVID-19

Overview
Journal Biomolecules
Publisher MDPI
Date 2022 Jan 21
PMID 35053224
Authors
Affiliations
Soon will be listed here.
Abstract

The angiotensin-converting enzyme 2 (ACE2) is a type I integral membrane that exists in two forms: the first is a transmembrane protein; the second is a soluble catalytic ectodomain of ACE2. The catalytic ectodomain of ACE2 undergoes shedding by a disintegrin and metalloproteinase domain-containing protein 17 (ADAM17), in which calmodulin mediates the calcium signaling pathway that is involved in ACE2 release, resulting in a soluble catalytic ectodomain of ACE2 that can be measured as soluble ACE2 plasma activity. The shedding of the ACE2 catalytic ectodomain plays a role in cardiac remodeling and endothelial dysfunction and is a predictor of all-cause mortality, including cardiovascular mortality. Moreover, considerable evidence supports that the ACE2 catalytic ectodomain is an essential entry receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Additionally, endotoxins and the pro-inflammatory cytokines interleukin (IL)-1β and tumor necrosis factor-alpha (TNFα) all enhanced soluble catalytic ectodomain ACE2 shedding from the airway epithelia, suggesting that the shedding of ACE2 may represent a mechanism by which viral entry and infection may be controlled such as some types of betacoronavirus. In this regard, ACE2 plays an important role in inflammation and thrombotic response, and its down-regulation may aggravate COVID-19 via the renin-angiotensin system, including by promoting pathological changes in lung injury. Soluble forms of ACE2 have recently been shown to inhibit SARS-CoV-2 infection. Furthermore, given that vitamin D enhanced the shedding of ACE2, some studies reported that vitamin D treatment is associated with prognosis improvement in COVID-19. This is an updated review on the evidence, clinical, and therapeutic applications of ACE2 for COVID-19.

Citing Articles

Phenotypic switch of vascular smooth muscle cells in COVID-19: Role of cholesterol, calcium, and phosphate.

Ghanem L, Essayli D, Kotaich J, Al Zein M, Sahebkar A, Eid A J Cell Physiol. 2024; 239(12):e31424.

PMID: 39188012 PMC: 11649971. DOI: 10.1002/jcp.31424.


The role of vitamin D/calmodulin/calcium signalling/ACE2 pathway in COVID-19.

Garcia-Escobar A, Vera-Vera S, Tebar-Marquez D, Jurado-Roman A, Jimenez-Valero S, Galeote G Br J Cardiol. 2024; 30(2):11.

PMID: 38911688 PMC: 11189159. DOI: 10.5837/bjc.2023.011.


Pathogenic mechanisms of cardiovascular damage in COVID-19.

Shao H, Yin R Mol Med. 2024; 30(1):92.

PMID: 38898389 PMC: 11186295. DOI: 10.1186/s10020-024-00855-2.


ACE-2-like enzymatic activity is associated with immunoglobulin in COVID-19 patients.

Song Y, Myers R, Mehl F, Murphy L, Brooks B, Wilson J mBio. 2024; 15(4):e0054124.

PMID: 38501835 PMC: 11005375. DOI: 10.1128/mbio.00541-24.


The role of angiotensin-converting enzyme 2 () genetic variations in COVID-19 infection: a literature review.

Fawzy M, Ashour H, Shafie A, Ben Hadj Dahman N, Fares A, Antar S Egypt J Med Hum Genet. 2023; 23(1):97.

PMID: 37521836 PMC: 9142348. DOI: 10.1186/s43042-022-00309-6.


References
1.
Qian Z, Travanty E, Oko L, Edeen K, Berglund A, Wang J . Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome-coronavirus. Am J Respir Cell Mol Biol. 2013; 48(6):742-8. PMC: 3727876. DOI: 10.1165/rcmb.2012-0339OC. View

2.
Zhang M, Abrams C, Wang L, Gizzi A, He L, Lin R . Structural basis for calmodulin as a dynamic calcium sensor. Structure. 2012; 20(5):911-23. PMC: 3372094. DOI: 10.1016/j.str.2012.03.019. View

3.
Bennouar S, Bachir Cherif A, Kessira A, Bennouar D, Abdi S . Vitamin D Deficiency and Low Serum Calcium as Predictors of Poor Prognosis in Patients with Severe COVID-19. J Am Coll Nutr. 2021; 40(2):104-110. PMC: 7814570. DOI: 10.1080/07315724.2020.1856013. View

4.
Daneshgaran G, Dubin D, Gould D . Cutaneous Manifestations of COVID-19: An Evidence-Based Review. Am J Clin Dermatol. 2020; 21(5):627-639. PMC: 7456663. DOI: 10.1007/s40257-020-00558-4. View

5.
Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View